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Abstract
Background: Germline mutations in the BRCA1 and BRCA2 genes greatly increase a woman’s risk of developing
breast and/or ovarian cancer. The prevalence and distribution of such mutations differ across races/ethnicities.
Several studies have investigated Chinese women with high-risk breast cancer, but the full spectrum of the
mutations in these two genes remains unclear.
Methods: In this study, 133 unrelated Chinese women with familial breast/ovarian cancer living in Zhejiang, eastern
China, were enrolled between the years 2008 and 2014. The complete coding regions and exon-intron boundaries
of BRCA1 and BRCA2 were screened by PCR-sequencing assay. Haplotype analysis was performed to confirm BRCA1
and BRCA2 founder mutations. In silico predictions were performed to identify the non-synonymous amino acid
changes that were likely to disrupt the functions of BRCA1 and BRCA2.
Results: A total of 23 deleterious mutations were detected in the two genes in 31 familial breast/ovarian cancer
patients with a total mutation frequency of 23.3 % (31/133). The highest frequency of 50.0 % (8/16) was found in
breast cancer patients with a history of ovarian cancer. The frequencies of BRCA1 and BRCA2 mutations were 13.5 %
(18/133) and 9.8 % (13/133), respectively. We identified five novel deleterious mutations (c.3295delC, c.3780_3781delAG,
c.4063_4066delAATC, c.5161 > T and c.5173insA) in BRCA1 and seven (c.1-40delGA, c.4487delC, c.469_473delAAGTC,
c.5495delC, c.6141T > A, c.6359C > G and c.7588C > T) in BRCA2, which accounted for 52.2 % (12/23) of the total
mutations. Six recurrent mutations were found, including four (c.3780_3781delAG, c.5154G > A, c.5468-1del8 and
c.5470_5477del8) in BRCA1 and two (c.3109C > T and c.5682C > G) in BRCA2. Two recurrent BRCA1 mutations
(c.5154G > A and c.5468-1del8) were identified as putative founder mutations. We also found 11 unclassified variants,
and nine of these are novel. The possibility was that each of the non-synonymous amino acid changes would disrupt
the function of BRCA1 and BRCA2 varied according to the different algorithms used.
Conclusions: BRCA1 and BRCA2 mutations accounted for a considerable proportion of hereditary breast/ovarian cancer
patients from eastern China and the spectrum of the mutations of these two genes exhibited some unique features.
The two BRCA1 putative founder mutations may provide a cost-effective option to screen Chinese population, while
founder effects of the two mutations should be investigated in a lager sample size of patients.
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Background
In 2009, the morbidity rate of breast cancer was 42.55 per
100,000 Chinese women, and breast cancer ranked first in
cancer incidence and fifth in cancer-related deaths among
females [1]. The mean age at diagnosis of breast cancer is
45–55 years in Chinese women, which is considerably
younger than that in western women [2]. A significant
proportion of breast cancer in Chinese women is caused
by genetic alterations. Germline mutations in many genes,
such as BRCA1, BRCA2, ATM, TP53, RAD51C and
XRCC2, have been identified to be associated with breast
cancer [3–5]. Several studies have investigated germline
mutations in genes including BRCA1, BRCA2, TP53,
BRIP1, PALB2, CHEK2, RAD50, NBS1 and RAD51C in
Chinese women with high risk breast cancer [6–21]. We
previously summarized the spectrum of the germline
mutations in these genes and found that the BRCA1 and
BRCA2 tumor suppressor genes are the two most import-
ant susceptibility genes and account for nearly 98 % of
hereditary breast cancer in China [22]. We found that the
spectrum of BRCA1 and BRCA2 germline mutations in
Chinese high risk breast cancer patients are much smaller
than those in Caucasian patients, and little has been
recognized in this field. The overall mutation frequencies
in these two genes in Chinese high risk breast cancer
patients ranged from 8.3 to 27.8 %, depending on the detec-
tion methods and patient inclusion criteria used. These fre-
quencies are much lower than the 25–40 % in BRCA1 and
6–15 % in BRCA2 that have been observed in Caucasian
populations [22]. Because germline mutations in BRCA1
and BRCA2 greatly increase a woman’s risk of developing
breast and/or ovarian cancer, and the prevalence and distri-
bution of the germline mutations differ in different races/
ethnicities, we were interested in identifying the full
spectrum of these mutations in high-risk female breast
cancer patients in the Chinese population.
In this study, we screened the entire coding regions and
exon-intron boundaries of the BRCA1 and BRCA2 genes in
133 familial breast/ovarian cancer patients from eastern
China. A total of 23 deleterious mutations, including 12
novel mutations (five in BRCA1 and seven in BRCA1), were
detected in these two genes in 31 familial breast/ovarian
cancer patients, and the total mutation frequency was
23.3 % (31/133). The highest frequency of 50.0 % (8/16)
was found in the breast cancer patients with a history of
ovarian cancer. Six recurrent mutations were found, includ-
ing four in BRCA1 and two in BRCA2. We also found 11
unclassified variants (UVs), nine of which were novel.
Additionally, using comparative evolutionary bioinformatic
programs, we identified the non-synonymous amino acid
changes that are likely to disrupt the functions of the
BRCA1 and BRCA2 genes. Our study suggested that
BRCA1 and BRCA2 mutations accounted for a consider-
able proportion of the hereditary breast/ovarian cancer
patients in eastern China and that the spectrum of the
mutations in these genes exhibited unique features.
Methods
Subjects
All patients were diagnosed between 2008 and 2014 in the
Zhejiang Cancer Hospital, eastern China. The criterion for
familial breast/ovarian cancer was that at least one first- or
second-degree relative of the breast cancer patient had been
affected by breast cancer and/or ovarian cancer, regardless
of age. Written consent was obtained from all participating
patients. The study was approved by the Research and
Ethics Committee of Zhejiang Cancer Hospital, China.
Peripheral blood samples were drawn from at least one
affected person in each family and stored in EDTA tubes at
−80 °C. A total of 133 patients from unrelated families were
enrolled in this study. For the 62 patients who enrolled
before 2012, the BRCA1 gene was analyzed with a polymer-
ase chain reaction (PCR)-sequencing assay as previously
reported [13], and the mutations of the BRCA2 gene were
screened in this study.
BRCA1 and BRCA2 mutation analysis
Genomic DNA was extracted from the peripheral blood
leukocytes of one patient from each family using a ZR
Genomic DNA Kit (Zymo Research, Orange County, CA,
USA) or a QIAamp DNA Blood Mini kit (Qiagen, Hilden,
Germany). The entire coding regions and exon-intron
boundaries of BRCA1 [U14680.1] and BRCA2 [U43746.1]
were screened using PCR-sequencing assay. Totals of 32
pairs and 40 pairs of primers for BRCA1 and BRCA2,
respectively, were synthesized by Invitrogen. The primers
and PCR conditions are available on request. The PCR
products were verified on standard agarose gels prior to
mutation analysis and purified by membrane retention.
The purified fragments were sequenced using a BigDye
Terminator Cycle Sequencing Kit and an ABI 3130xl
Genetic Analyzer (Applied Biosystems, Foster City, CA,
USA). All mutations were confirmed by duplicate
independent PCR. No screening for large genomic rear-
rangements was performed.
All of the mutations and variants were named according
to the Human Genome Variation Sequence systematic
nomenclature (HGVS; http://www.hgvs.org/mutnomen/).
The Breast Cancer Information Core (BIC) nomenclature
(https://research.nhgri.nih.gov/projects/bic/Member/index.
shtml) was also indicated in the tables and text because
this system had been widely employed in many studies.
All of the mutations and variants were queried against the
1000 Genomes database using the 1000 Genomes Browser
(http://browser.1000genomes.org/) to determine whether
the mutations and variants had been reported in the
Chinese population.
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Haplotype analysis
Haplotype analysis was conducted on the unrelated
patients with recurrent BRCA1 or BRCA2 germline dele-
terious mutations. Thirteen microsatellite polymorphic
loci were used (BRCA1 D17S855, D17S1322, D17S1323,
D17S1326, D17S1327; BRCA2 D13S1304, D13S217,
D13S289, D13S1699, D13S1698, D13S171, D13S1695,
D13S267) [9, 12]. Primer sequences of all microsatellite
polymorphic loci were obtained from the Probe Database
(http://www.ncbi.nlm.nih.gov/probe). PCR products fluo-
rescently labeled were size fractioned on an ABI 3730xl
Analyzer (Applied Biosystems) using GeneScan 500 LIZ
Size Standard. Analysis was performed using the Gene-
marker v1.5 analysis software.
In silico prediction
To identify the UVs that were likely to disrupt the func-
tions of the BRCA1 and BRCA2 genes, we performed in
silico predictions with the following six comparative evo-
lutionary bioinformatic programs: Align-GVGD (http://
agvgd.iarc.fr/agvgd_input.php), SIFT (http://sift.jcvi.org/),
PROVEAN (http://provean.jcvi.org/index.php), PolyPhen-
2 (http://genetics.bwh.harvard.edu/pph/), PMUT (http://
mmb2.pcb.ub.es:8080/PMut/), and PANTHER (http://
www.pantherdb.org/tools/csnpScoreForm.jsp).
Statistical analysis
Continuous data were presented as the mean ± standard
deviation (SD), and the differences between the two
groups were evaluated using one-way ANOVA analyses.
Frequencies were calculated as the proportion of mutation
carriers among all participants. The differences in the
overall frequencies of BRCA1 and BRCA2 mutations
between groups were evaluated using Chi-square tests and
Fisher’s exact tests. The statistics were performed using
SPSS version 17.0 software for Windows.
Results
Patient features
A total of 133 unrelated patients with personal and family
histories of breast and/or ovarian cancer underwent BRCA1
and BRCA2 germline mutation screening. All of the
patients were from the Zhejiang province in eastern China.
In our cohort of 133 breast cancer families, there were 2.3
± 0.7 (mean number ± SD) occurrences of breast cancer
per family. The age of breast cancer onset ranged from
22 years to 74 years. The mean age at diagnosis was 43.0
± 9.3 (mean age ± SD) years. Ovarian cancer was present
in 12.0 % (16/133) of all families.
BRCA1 deleterious mutations
In this cohort of 133 familial breast/ovarian cancer patients,
13 deleterious mutations in BRCA1 were found in 18 unre-
lated patients, including five mutations that were reported
in our previous study [13] (Table 1). None of the mutations
had been registered in the 1000 Genomes database. The
majority of the mutations were either nonsense or frame-
shift mutations with the exception of c.5467 + 1G >A and
c.5468-1del8. Six mutations (46.2 %) were located in exon
11, and others were located in exon 19, exon 20, intron 23
and exon 24. There were five novel deleterious mutations
(c.3295delC, c.3780_3781delAG, c.4063_4066delAATC,
c.5161C > T and c.5173insA) that had not been registered
in the BIC or any other public database. Moreover, two of
the mutations (c.5468-1del8 and c.1465G >T) had only been
previously reported in Chinese population. In this cohort,
we detected four recurrent mutations (c.3780_3781delAG,
c.5154G >A, c.5468-1del8 and c.5470_5477del8), which
accounted for 30.8 % (4/13) of the total mutations. The
mutation c.5470_5477del8 occurred three times, and the
others occurred twice. The mean age at diagnosis of these
BRCA1 mutation carriers was 39.9 ± 8.1 (mean age ± SD)
years (Table 2). No significant differences in the mean age
at diagnosis between the BRCA1 mutation carriers,
BRCA2 mutation carriers and non-carriers were found.
BRCA2 deleterious mutations
A total of 10 deleterious mutations in BRCA2 were found
in 13 familial breast/ovarian cancer patients in this cohort
(Table 1). None of these mutations had been registered in
the 1000 Genomes database. The mean age at diagnosis of
these BRCA2 mutation carriers was 41.1 ± 6.5 (mean age ±
SD) years (Table 2). Nine mutations were either nonsense
or frameshift mutation, and the remaining mutation c.1-
40delGA, which resulted in the deletion of a guanine in
intron 1 and an adenine in exon 2, was a splicing site muta-
tion. Sixty percent (6/10) of the all of the mutations were
located in exon 11. There were seven novel mutations (c.1-
40delGA, c.4487delC, c. 469_473delAAGTC, c.5495delC,
c.6141 T >A, c.6359C >G and c.7588C >T) in this cohort,
and these mutations represented 70 % (7/10) of the muta-
tions in this gene. Two recurrent mutations (c.3109C >T
and c.5682C >G) were detected in this cohort, and both of
them were registered in the BIC.
Frequencies of BRCA1 and BRCA2 deleterious mutations
A total of 23 deleterious mutations of BRCA1 and BRCA2
were identified in 31 familial breast/ovarian cancer patients,
and the frequency was 23.3 % (31/133; Table 3). The
frequencies of BRCA1 and BRCA2 mutations were 13.5 %
(18/133) and 9.8 % (13/133), respectively.
In the subgroup analysis, the highest overall BRCA1 and
BRCA2 mutations rate was 50.0 % (8/16) in the breast
cancer patients with family histories of ovarian cancer. The
overall mutation rate of the two genes in the patients who
were diagnosed at or before the age of 40 was higher than
that of the counterpart group. Compared with the breast
cancer patients with fewer than two relatives affected by
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breast cancer or unilateral breast cancer, the overall muta-
tion rates were higher in the patients with two or more rel-
atives affected by breast cancer or bilateral breast cancer,
but these differences did not reach statistical significance
(P = 0.148 and P = 0.115, respectively).
Haplotype analysis of recurrent mutations
Four recurrent BRCA1 mutations (c.3780_3781delAG,
c.5154G >A, c.5468-1del8 and c.5470_5477del8) and two
recurrent BRCA2 mutations (c.3109C >T and c.5682C >G)
were identified in unrelated breast cancer patients. As
haplotype analysis of BRCA1 c.5470_5477del8 mutation
and BRCA2 c.3109C >T mutation had been performed in
Chinese high risk breast cancer patients [9, 10, 12], we
performed haplotype analysis on the other four recurrent
mutations in this study. Our results showed that carriers
with the recurrent BRCA1 c.5154G >A mutation shared
the same haplotype, as well as carriers with the recurrent
BRCA1 c.5468-1del8 mutation, which suggested that these
two putative founder mutations were derived from a com-
mon ancestor (Table 4). The three carriers with BRCA2
c.5682C >G mutation sharing only two alleles (D13S171
and D13S1698) out of eight alleles implied that they might
be not derived from a common ancestor (Table 5).
UVs of BRCA1 and BRCA2
In addition to deleterious mutations, we identified 11 UVs
(seven in BRCA1 and four in BRCA2; Table 6). Compari-
sons with the 1000 Genomes database revealed that only
BRCA1 c.2286A > T (R762S) had been reported in a
Pakistani population, and the frequency of the T allele was
0.5 % in that population. None of the UVs had previously
been found in the Chinese population. The majority of the
variants were novel, with the exception of the mutation
c.2286A > T in BRCA1, which is registered in the BIC, and
c.2726A > T in BRCA1, which was recently reported in a
Table 1 BRCA1 and BRCA2 deleterious germline mutations in 133 Chinese women with familial breast/ovarian cancer
Gene No. of patient Exon Systematic nomenclature BIC nomenclature Amino acid change References
BRCA1 1 11 c.1465G > T 1584G > T E489X Zhi et al. [7]
1 11 c.1945G > T 2064G > T E649X BIC
1 11 c.3295delC 3414delC P1099LfsX10 Novel
2 11 c.3780_3781delAG 3899_3900delAG L1260FfsX6 Novel
1 11 c.4063_4066delAATC 4182_4185delAATC N1355KfsX10 Novel
1 11 c.4065_4068delTCAA 4184_4187delTCAA N1355KfsX10 BIC
2 19 c.5154G > A 5273G > A W1718X BIC
1 19 c.5161C > T 5280C > T Q1721X Novel
1 19 c.5173insA 5292insA E1725EfsX7 Novel
1 20 c.5251C > T 5370C > T R1751X BIC
1 Intron23 c.5467 + 1G > A IVS23 + 1G > A Splicing defect BIC
2 Intron23 c.5468-1del8 5587-1del8 Splicing defect Zhang et al. [11]
3 24 c.5470_5477del8 5589_5596del8 I1824DfsX3 BIC
BRCA2 1 Intron1 c.1-40delGA IVS1-1deGA Splicing defect Novel
1 5 c.469_473delAAGTC 697_701delAAGTC K157SfsX24 Novel
1 9 c.755_758delACAG 983_986delACAG T251XfsX1 BIC
2 11 c.3109C > T 3337C > T Q1037X BIC
1 11 c.4487delC 4715delC P1496QfsX8 Novel
1 11 c.5495delC 5723delC S1832LfsX8 Novel
3 11 c.5682C > G 5910C > G Y1894X BIC
1 11 c.6141 T > A 6369 T > A Y2047X Novel
1 11 c.6359C > G 6587C > G S2120X Novel
1 15 c.7588C > T 7816C > T Q2530X Novel
BIC Breast Cancer Information Core
Table 2 Mean age at diagnosis in different BRCA1 and BRCA2
status
BRCA1 BRCA2 Non-carriers Pa Pb Pc
Number 18 13 102
Mean age (±SD) 39.9 (±8.1) 41.1 (±6.5) 43.9 (±9.7) 0.74 0.11 0.31
SD standard deviation
aBRCA1 compare to BRCA2 mutation carriers
bBRCA1 mutation carriers compare to non-carriers
cBRCA2 mutation carriers compare to non-carriers
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Chinese population previously [8]. The possibility that
each of the UVs would disrupt the function of BRCA1 or
BRCA2 was predicted in silico, and the results varied
according to the different algorithms used.
Discussion
BRCA1 and BRCA2 are the most important genetic suscep-
tibility genes for breast/ovarian cancer in both Caucasian
and Chinese populations. The spectrum and frequencies of
mutations in these two genes in Chinese women with
familial breast/ovarian cancer have been insufficiently
explored to date. Moreover, the penetrance has not yet
been investigated. Due to the limited knowledge on heredi-
tary breast/ovarian cancer, there is no genetic counseling or
testing services available in Mainland China.
Our results demonstrated that the frequency of BRCA1
and BRCA2 mutations among Chinese women with famil-
ial breast/ovarian cancer was 23.3 %. Similar results have
been reported in the Korean population [23], Hispanic
population [24] and Africa American population [25].
However, the frequency observed in the current study is
lower than that reported in an Ashkenazi Jewish popula-
tion, in which the frequency of BRCA1 and BRCA2
mutations was 69 % [25]. Compared with other reports
about Chinese populations, the frequency found in our
cohort was the highest in patients with familial breast/
ovarian cancer. Li et al. [9] used PCR-DHPLC assay to
screen for BRCA1 and BRCA2 mutations in 241 women
with familial breast cancer from northern or southern
China and found a frequency of 12.9 %. Although the
PCR-DHPLC assay is cost-effective for screening for gen-
etic mutations, a considerable number of disease-
associated mutations may have been missed by this indir-
ect detection method [26]. Zhang et al. [11] reported that
the frequency of BRCA1 and BRCA2 mutations in north-
ern Chinese familial breast cancer patients was 10.5 %
(43/409) based on PCR-sequencing assay. The enrolment
criteria and mutation detecting assay used in this were
comparable with the criteria used in our study, but the re-
ported frequency was much lower than that observed in
the present study. In their subgroup analysis, the highest
frequency was 23 % in the patients whose tumors had
been diagnosed at or before the age of 40 years. However,
the frequency reached 33.3 % in this group of patients in
our cohort. Moreover, in the study conducted by Kwong
et al., [12] the frequency of BRCA1 and BRCA2 mutations
in high-risk breast/ovarian cancer patients was 15.3 % (69/
Table 3 Frequencies of BRCA1 and BRCA2 germline deleterious mutations in different groups of patients
Features Number of total cases BRCA1 mutation (%) BRCA2 mutation (%) Overall mutation (%) P-value
Total 133 18 (13.5) 13 (9.8) 31 (23.3)
Age at onset
≤40 years 51 11 (21.6) 6 (11.8) 17 (33.3) 0.031
>40 years 82 7 (8.5) 7 (8.5) 14 (17.1)
Number of breast cancer cases in a family
≤2 99 12 (12.1) 8 (8.1) 20 (20.2) 0.148
>2 34 6 (17.6) 5 (14.7) 11 (32.4)
With a family history of ovarian cancer
Yes 16 6 (37.5) 2 (12.5) 8 (50.0) 0.012
No 117 12 (10.3) 11 (9.4) 23 (19.7)
Bilateral breast cancer
Yes 15 3 (20) 3 (20) 6 (40) 0.115
No 118 15 (12.7) 10 (8.5) 25 (21.2)
Table 4 Haplotype analysis of BRCA1 recurrent mutations carriers
Mutation Patient No. D17S855 D17S1322 D17S1323 D17S1326 D17S1327
c.3780_3781delAG 1 145/147 113/116 150/152 108/110 128/130
2 141/143 119/122 156/160 86/88 158/160
c.5154G > A 3 143/141 122/119 156/156 90/88 154/152
4 143/151 122/116 156/152 90/104 154/130
c.5468-1del8 5 147/141 116/122 152/146 104/106 128/130
6 147/145 116/113 152/150 104/102 128/130
Shared haplotypes are bolded
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651). These authors also employed the conventional PCR-
sequencing assay, and the patients were recruited from
southern China. The proportion of high-risk breast/ovarian
cancer patients, including familial breast cancer patients
and early-onset cases and the frequency of two-gene muta-
tions were much lower in the early-onset patients than in
the familial breast cancer cases. Large genomic rearrange-
ments account for 4–28 % of all BRCA1 and BRCA2 muta-
tions [27], and such mutations have been found in Chinese
women at a high risk for breast cancer [28–32]. Because
the PCR-sequencing assay cannot detect these rearrange-
ments, the frequency of mutations in our cohort might
have been underestimated, and the frequency of BRCA1
and BRCA2 mutations in the eastern Chinese population
could be significant.
Although several studies have reported that the BRCA2
mutations are more frequent than BRCA1 mutations in
Asian population [11, 12, 33, 34], BRCA1 mutations
seemed to be more prevalent in our cohort. This finding
might be attributable to two points. First, most studies have
reported that BRCA2 mutations predominantly occur in
relatively late-onset breast cancer patients compared with
BRCA1 mutations [11, 35], but the patients enrolled in our
study were much younger than those in other studies,
which might have resulted in an underestimation of the
contribution of BRCA2 mutations. Second, a greater num-
ber of recurrent mutations were found in BRCA1 than in
BRCA2 in our study, which elevated the frequency of
BRCA1 mutations.
In the present study, we found that 52.2 % (12/23) of the
deleterious mutations were novel; these mutations included
five mutations in BRCA1 and seven mutations in BRCA2.
In our previous systemic analysis of the spectrum of
BRCA1 and BRCA2 mutations in Han Chinese women, we
reported that 56.3 % (40/71) and 47.9 % (35/73) of the
BRCA1 and BRCA2 mutations were novel, respectively
[22]. It seems that the spectrum of BRCA1 and BRCA2
mutations in Chinese women exhibit unique features. The
BRCA2 mutation c.1-40delGA in our cohort was novel.
Bakker et al. [36] found a BRCA2 c.1-40 G >A mutation in
a Japanese Fanconi anemia family. The functional analysis
of these authors used a mouse embryonic stem cell-based
assay that revealed that this mutation caused aberrant spli-
cing, reduced transcript levels and hypersensitivity to DNA
damaging agents, suggesting that this mutation was likely
pathogenic. These authors thought that this finding was
relevant for mutation analysis in hereditary breast and
ovarian cancer syndrome families in a diagnostic setting.
The mutation c.1-40delGA, which deletes a guanine in in-
tron 1 and an adenine in exon 2 and causes the loss of the
donor site of intron 1, should also be pathogenic.
Six BRCA1 and BRCA2 recurrent mutations were iden-
tified in multiple patients, and these accounted for 45.2 %
(14/31) of the total patients with mutations. Of these
mutations, one (c.3780_3781delAG) was novel, another
(c.5468-1del8) was recently reported in Chinese women
[11], and the remaining four had been reported in the BIC
database. Founder mutations provide population-specific
genetic risk assessment, and facilitate genetic mutation
screening. Thus far, few studies have suggested that
putative founder mutations of BRCA1 and BRCA2 might
exist in Chinese women at a high risk for breast cancer,
such as the c.981delAT and c.5470_5477del8 mutations
in BRCA1 and the c.3109C > T, c.7436_7805del370 and
c.9097_9098insA mutations in BRCA2 [9, 10, 12]. In our
cohort, the BRCA1 c.5470_5477del8 mutation and BRCA2
c.3109C > T mutation were both recurrent, but no other
three putative founder mutations was found. Our haplo-
type analysis revealed that BRCA1 c.5154G >A and
c.5468-1del8 mutations were the two putative founder
mutations. Since there are only two patients reported for
each of the putative founder mutation, the founder effects
are needed to be investigated by larger sample size of
patients. In our previous study, we reported that the most
common recurrent mutations in Chinese women at high
risk for breast cancer are c.5470_5477del8 in BRCA1 and
c.3109C > T in BRCA2 [22], which were reported to be
the putative founder mutations. However, the study that
enrolled the greatest number of familial breast cancer
patients from northern China did not find these six puta-
tive founder mutations except the BRCA1 c.5468-1del8
mutation [11]. The discrepancy regarding the founder
mutations in Chinese familial breast cancer patients may
be due to geographic differences. The characterization of
BRCA1 and BRCA2 founder mutations and association
between the founder mutations and breast cancer risk
should be studied in a large-scale Chinese population size.
Although, elevated mutation rates of BRCA1 and BRCA2
were found in patients who had been diagnosed at or
before 40 years of age, no significant differences were found
between the BRCA1 mutation carriers, BRCA2 mutation
carriers and non-carriers when compared to a mean age at
Table 5 Haplotype analysis of BRCA2 c.5682C > G mutation carriers
Patient No. D13S171 D13S217 D13S267 D13S289 D13S1304 D13S1695 D13S1698 D13S1699
7 224/238 164/172 144/151 146/156 157/159 211/215 158/156 161/163
8 224/224 168/170 151/159 144/156 153/155 209/213 158/156 157/155
9 224/228 164/160 144/142 146/144 153/149 211/207 158/160 157/159
Shared haplotypes are bolded
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SIFT PROVEAN PolyPhen-2 PMUT PANTHER
BRCA1 1 11 c.1679A > T 1798A > T D560V Novel C0 Damaging Deleterious Possibly
damaging
Neutral Deleterious
1 11 c.1537C > G 1656C > G H513D novel C0 Tolerated Deleterious Benign Pathological Neutral
1 11 c.2286A > T 2405A > T R762S BIC C0 Damaging Deleterious Benign Pathological Neutral
1 14 c.4445A > C 4564A > C D1482A novel C0 Damaging Neutral Benign Pathological Neutral
1 11 c.1966A > T 2085A > T N656Y novel C0 Damaging Deleterious Possibly
damaging
Neutral Deleterious
1 11 c.2340G > T 2459G > T Q780H novel C0 Damaging Deleterious Probably
damaging
Neutral Deleterious
1 11 c.2726A > T 2845A > T N909I BIC, Thirthagiri et al.
[8]
C0 Damaging Deleterious Possibly
damaging
Neutral Neutral
BRCA2 1 10 c.1568A > G 1796A > G H523R novel C0 Damaging Neutral Benign Pathological Neutral
1 11 c.3904A > G 4132A > G T1302A novel C0 Tolerated Deleterious Benign Neutral Neutral
1 11 c.5590G > A 5818G > A D1864N novel C0 Damaging Neutral Benign Neutral Neutral














diagnosis. The inconsistent results implied that these
observations did not withstand multiple comparisons in
our cohort. Breast cancer patients with family histories of
ovarian cancer exhibited the highest overall mutation rate
of BRCA1 and BRCA2, which implied that BRCA1 and
BRCA2 mutations are more likely to occur in families with
a history of both breast and ovarian cancer. This result is
consistent with those of other studies [9, 11].
Eleven UVs were found in our study, and the potentials
for these variants to disrupt the functions of BRCA1 and
BRCA2 varied according to the algorithm program used.
The UVs accounted for nearly 1/3 of the total mutations/
variants in this study. The risks of breast and ovarian
cancer in the UVs carriers might be as high as those in the
carriers of the classical pathogenic mutations. A variety of
approaches have been used to investigate the clinical rele-
vance of these UVs. Co-segregation analysis is regarded as a
robust approach because it is directly related to the disease
risk and is not affected by selection bias [37]. The absence
of co-segregation provides strong evidence against patho-
genicity. Unfortunately, the samples required for us to
perform co-segregation analysis of UVs and the deleterious
mutations in the multi-tumor families were not available.
Conclusions
In the present study, we found that the frequency of
BRCA1 and BRCA2 mutations was 23.3 % in our cohort of
133 Chinese women with familial breast/ovarian cancer,
and the frequency of BRCA1 and BRCA2 mutations was
50 % in patients with a familial history of both breast can-
cer and ovarian cancer. The spectrum of BRCA1 and
BRCA2 mutations in the Chinese population are quite
different from those in other ethnicities. Six recurrent
mutations were detected in this study, in which two recur-
rent BRCA1 mutations were identified as putative founder
mutations, and a larger sample size is required to determine
the founder effects of these two mutations in Chinese
women. BRCA1 and BRCA2 mutations account for a con-
siderable proportion of Chinese hereditary breast/ovarian
cancer patients, and the penetrance of these two genes
should be investigated because such investigations will be
very important for the development of a preventive treat-
ment strategy in China.
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